🔴An Act relating to the Texas Pharmaceutical Initiative
HB 4638
🔴 HB 4638: Governor-Controlled Drug Board Extends to 2031
What it says it does:
HB 4638 claims to lower prescription drug costs by expanding the Texas Pharmaceutical Initiative, a state program created to negotiate and manage medication prices. It adds more board members, extends the program timeline, and requires a business plan every two years.
What it actually changes:
The board grows from three to five members, all appointed by the Governor, each serving six-year terms. The bill extends the program’s expiration to 2031, giving the board broad new powers to contract with pharmacy benefit managers, build distribution centers, and even manufacture generic drugs and gene therapies.
Who is pushing for it:
Supporters listed in the files include AARP Texas, the Texas Pharmacy Association, the Texas Pharmacy Business Council, and the Texas Chapter of the American College of Physicians. The Texas Pharmaceutical Initiative itself testified in favor.
Who benefits:
Trade associations and large pharmacy networks could secure long-term contracts through the new statewide procurement powers. The Governor’s office gains control over a multi-billion-dollar pharmaceutical system with limited outside review.
Who gets left out or exposed:
Independent pharmacies may lose access if the state chooses preferred networks. Patients could see fewer options if contracts limit participation. Taxpayers face financial exposure if the board’s new projects outgrow existing budgets.
Why this matters long term:
This bill locks key health decisions inside an executive-appointed board that will not face legislative review for six years. It reduces public oversight, creates long-term contracting power without built-in audits, and sets a precedent for privatized control over essential state health programs.
What to watch next:
Track how the board allocates contracts for pharmacy benefit managers and distribution systems. Watch for manufacturing deals or partnerships that bypass competitive bidding. The next biennial plan will show whether the program stays focused on affordability or becomes a vehicle for insider control.
Bottom line:
HB 4638 sells the idea of cheaper medicine but centralizes pharmaceutical power under a governor-appointed board with limited transparency and long-term control over state health spending.
#HB4638 #TexasPolicy #Healthcare #PublicFunds #StayInformed